Eli Lilly is committing $4.5 billion to two Indiana manufacturing sites, and the first has already opened its doors. Lilly Lebanon Advanced Therapies, the company’s first dedicated genetic medicine building, is designed to produce genetic therapy modalities from research-stage work through large-scale commercial activities. To get there, Lilly says it had to build entirely new manufacturing processes from scratch.
The second site is where the real scale sits. Lilly Lebanon API, also funded by the $4.5 billion commitment, is expected to become the largest API production site in U.S. history, according to CEO David Ricks. It’s slated to open sometime next year.
What does Lilly get at Lebanon API? Zepbound and Mounjaro, the company’s approved GLP-1 injectables for weight management and type 2 diabetes, were already on the production list. Now the site adds Foundayo, Lilly’s newly marketed obesity pill, and retatrutide, its experimental triple hormone receptor agonist in testing for obesity and cardiometabolic disease.
The $4.5 billion joins a much larger stack. Since 2020, Lilly has poured more than $21 billion into Indiana manufacturing, all of it tied to obesity drug demand. Lilly cited its “evolving pipeline, as well as anticipated demand for its medicines” as the drivers.
Lebanon is now the center of Lilly’s U.S. manufacturing strategy. With an API plant that doesn’t open until next year and a gene therapy site that just opened, Lilly is building ahead of demand rather than chasing it.
Diana Kowalski